| Name | Title | Contact Details |
|---|
On the Forefront of COVID-19 Recognized leader in the COVID-19 field by governmental and non-governmental organizations as the reference assay...
Emendo biotherapeutics develops next generation gene editing tools for genetic disorders, addressing the current technological gaps for realizing the promise of gene therapy.
XTuit Pharmaceuticals, Inc. is a biopharmaceutical company developing novel microenvironment-activated therapeutics targeting key mechanisms resulting in hypoxia, decreased drug uptake, drug resistance, and decreased immune response. The Company’s proprietary drug development pipeline and integrated, sophisticated clinical biomarker platform will be used for accelerated clinical development across selected cancers and fibrotic disorders. XTuit’s compounds act through pleiotropic mechanisms to inhibit extracellular matrix synthesis and stabilization, and to silence activated stromal cells, including cancer-associated fibroblasts and stellate cells. As a result, XTuit compounds alleviate hypoxia and enable enhanced drug uptake through solid stress reduction. Moreover, the drugs have been shown to down-regulate stroma-induced tumor and inflammation signaling pathways to overcome treatment resistance. XTuit’s first two lead series are being developed for early clinical proof-of-concept in liver diseases and cancer.
Acumen Pharmaceuticals is a Livermore, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Stat-Tech Services is a Chapel Hill, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.